Secukinumab improves quality of life for patients with psoriasis

BOSTON — Quality of life improvements were recorded in most pediatric patients with psoriasis who received secukinumab, according to a poster presented at the American Academy of Dermatology Annual Meeting.
“For pediatric patients with psoriasis, clearance or near clearance of skin symptoms is associated with the greatest improvements in quality of life,” John Browning, MD, of The University of Texas at San Antonio, and colleagues wrote. “Secukinumab rapidly improved skin symptoms as determined by PASI and quality of life as measured by [Children’s DLQI (CDLQI)]

BOSTON — Quality of life improvements were recorded in most pediatric patients with psoriasis who received secukinumab, according to a poster presented at the American Academy of Dermatology Annual Meeting.
“For pediatric patients with psoriasis, clearance or near clearance of skin symptoms is associated with the greatest improvements in quality of life,” John Browning, MD, of The University of Texas at San Antonio, and colleagues wrote. “Secukinumab rapidly improved skin symptoms as determined by PASI and quality of life as measured by [Children’s DLQI (CDLQI)]